241 related articles for article (PubMed ID: 22045655)
1. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1.
Abusnina A; Keravis T; Yougbaré I; Bronner C; Lugnier C
Mol Nutr Food Res; 2011 Nov; 55(11):1677-89. PubMed ID: 22045655
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis.
Abusnina A; Alhosin M; Keravis T; Muller CD; Fuhrmann G; Bronner C; Lugnier C
Cell Signal; 2011 Jan; 23(1):152-60. PubMed ID: 20807569
[TBL] [Abstract][Full Text] [Related]
3. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
[TBL] [Abstract][Full Text] [Related]
4. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
6. The flavonoid dioclein is a selective inhibitor of cyclic nucleotide phosphodiesterase type 1 (PDE1) and a cGMP-dependent protein kinase (PKG) vasorelaxant in human vascular tissue.
Gonçalves RL; Lugnier C; Keravis T; Lopes MJ; Fantini FA; Schmitt M; Cortes SF; Lemos VS
Eur J Pharmacol; 2009 Oct; 620(1-3):78-83. PubMed ID: 19686719
[TBL] [Abstract][Full Text] [Related]
7. PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.
Khammy MM; Dalsgaard T; Larsen PH; Christoffersen CT; Clausen D; Rasmussen LK; Folkersen L; Grunnet M; Kehler J; Aalkjaer C; Nielsen J
Br J Pharmacol; 2017 Nov; 174(22):4186-4198. PubMed ID: 28910498
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
[TBL] [Abstract][Full Text] [Related]
9. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines.
Fallahian F; Karami-Tehrani F; Salami S; Aghaei M
FEBS J; 2011 Sep; 278(18):3360-9. PubMed ID: 21777390
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells.
Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
Biochem Pharmacol; 2005 Jan; 69(2):267-75. PubMed ID: 15627479
[TBL] [Abstract][Full Text] [Related]
11. Characterization of phosphodiesterase 1 in human malignant melanoma cell lines.
Shimizu K; Murata T; Watanabe Y; Sato C; Morita H; Tagawa T
Anticancer Res; 2009 Apr; 29(4):1119-22. PubMed ID: 19414353
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
14. Profiling of functional phosphodiesterase in mesangial cells using a CRE-SEAP-based reporting system.
Zhu Y; Yao J; Meng Y; Kasai A; Hiramatsu N; Hayakawa K; Miida T; Takeda M; Okada M; Kitamura M
Br J Pharmacol; 2006 Jul; 148(6):833-44. PubMed ID: 16751794
[TBL] [Abstract][Full Text] [Related]
15. Cross talk between NO and cyclic nucleotide phosphodiesterases in the modulation of signal transduction in blood vessel.
Lugnier C; Keravis T; Eckly-Michel A
J Physiol Pharmacol; 1999 Dec; 50(4):639-52. PubMed ID: 10639014
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibition by a gastroprotective agent irsogladine: preferential blockade of cAMP hydrolysis.
Kyoi T; Oka M; Noda K; Ukai Y
Life Sci; 2004 Aug; 75(15):1833-42. PubMed ID: 15302227
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase profile of human B lymphocytes from normal and atopic donors and the effects of PDE inhibition on B cell proliferation.
Gantner F; Götz C; Gekeler V; Schudt C; Wendel A; Hatzelmann A
Br J Pharmacol; 1998 Mar; 123(6):1031-8. PubMed ID: 9559883
[TBL] [Abstract][Full Text] [Related]
18. A novel PDE1A coupled to M2AChR at plasma membranes from bovine tracheal smooth muscle.
Mastromatteo-Alberga P; Placeres-Uray F; Alfonzo-González MA; Alfonzo RG; Becemberg IL; Alfonzo MJ
J Recept Signal Transduct Res; 2016; 36(3):278-87. PubMed ID: 26513204
[TBL] [Abstract][Full Text] [Related]
19. Expression and role of phosphodiesterase 5 in human malignant melanoma cell line.
Murata T; Shimizu K; Watanabe Y; Morita H; Sekida M; Tagawa T
Anticancer Res; 2010 Feb; 30(2):355-8. PubMed ID: 20332439
[TBL] [Abstract][Full Text] [Related]
20. Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells.
Wang CC; Chiang YM; Sung SC; Hsu YL; Chang JK; Kuo PL
Cancer Lett; 2008 Jan; 259(1):82-98. PubMed ID: 18023967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
